DE2732614A1 - Arzneimittel mit wirkung auf das zentralnervensystem - Google Patents
Arzneimittel mit wirkung auf das zentralnervensystemInfo
- Publication number
- DE2732614A1 DE2732614A1 DE19772732614 DE2732614A DE2732614A1 DE 2732614 A1 DE2732614 A1 DE 2732614A1 DE 19772732614 DE19772732614 DE 19772732614 DE 2732614 A DE2732614 A DE 2732614A DE 2732614 A1 DE2732614 A1 DE 2732614A1
- Authority
- DE
- Germany
- Prior art keywords
- group
- butyric acid
- phenyl
- fluoro
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940126601 medicinal product Drugs 0.000 title claims 10
- 210000003169 central nervous system Anatomy 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 10
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 9
- 229960001076 chlorpromazine Drugs 0.000 claims description 9
- 230000000701 neuroleptic effect Effects 0.000 claims description 9
- 159000000000 sodium salts Chemical class 0.000 claims description 9
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 8
- 239000003176 neuroleptic agent Substances 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 229960003878 haloperidol Drugs 0.000 claims description 6
- 229940124277 aminobutyric acid Drugs 0.000 claims description 5
- 230000003287 optical effect Effects 0.000 claims description 5
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 claims description 2
- HRRFDYCXYAHGQN-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]pyrrolidine Chemical compound C1=CC(F)=CC=C1CN1CCCC1 HRRFDYCXYAHGQN-UHFFFAOYSA-N 0.000 claims description 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- ILUJQPXNXACGAN-UHFFFAOYSA-N O-methylsalicylic acid Chemical class COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 claims description 2
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical group 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 229960004170 clozapine Drugs 0.000 claims description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 125000004436 sodium atom Chemical group 0.000 claims description 2
- 229960004940 sulpiride Drugs 0.000 claims description 2
- 229960002784 thioridazine Drugs 0.000 claims description 2
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 9
- GTKYLVJCMKDNTH-UHFFFAOYSA-N 2-methoxy-5-sulfamoylbenzamide Chemical compound COC1=CC=C(S(N)(=O)=O)C=C1C(N)=O GTKYLVJCMKDNTH-UHFFFAOYSA-N 0.000 claims 2
- 238000005744 Teer Meer reaction Methods 0.000 claims 2
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims 1
- 208000009132 Catalepsy Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 206010047853 Waxy flexibility Diseases 0.000 description 5
- 230000002903 catalepsic effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108010060511 4-Aminobutyrate Transaminase Proteins 0.000 description 1
- 102100035923 4-aminobutyrate aminotransferase, mitochondrial Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001484 cataleptigenic effect Effects 0.000 description 1
- 210000001159 caudate nucleus Anatomy 0.000 description 1
- 229940084512 chlorpromazine 100 mg Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000003371 gabaergic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7622045A FR2358881A1 (fr) | 1976-07-20 | 1976-07-20 | Composition pharmaceutique active sur le systeme nerveux central |
| FR7719390A FR2453643A2 (fr) | 1977-06-24 | 1977-06-24 | Compositions pharmaceutiques actives sur le systeme nerveux central |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2732614A1 true DE2732614A1 (de) | 1978-01-26 |
Family
ID=26219550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19772732614 Withdrawn DE2732614A1 (de) | 1976-07-20 | 1977-07-19 | Arzneimittel mit wirkung auf das zentralnervensystem |
Country Status (11)
-
1977
- 1977-07-18 NZ NZ184666A patent/NZ184666A/xx unknown
- 1977-07-18 IL IL52550A patent/IL52550A/xx unknown
- 1977-07-19 IE IE1509/77A patent/IE45454B1/en unknown
- 1977-07-19 GB GB30355/77A patent/GB1556567A/en not_active Expired
- 1977-07-19 CA CA283,049A patent/CA1077846A/en not_active Expired
- 1977-07-19 LU LU77796A patent/LU77796A1/xx unknown
- 1977-07-19 SE SE7708349A patent/SE7708349L/ not_active Application Discontinuation
- 1977-07-19 AU AU27151/77A patent/AU508753B2/en not_active Expired
- 1977-07-19 DE DE19772732614 patent/DE2732614A1/de not_active Withdrawn
- 1977-07-20 JP JP8785277A patent/JPS5326327A/ja active Pending
- 1977-07-20 NL NL7708055A patent/NL7708055A/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ184666A (en) | 1980-04-28 |
| JPS5326327A (en) | 1978-03-11 |
| NL7708055A (nl) | 1978-01-24 |
| AU508753B2 (en) | 1980-04-03 |
| SE7708349L (sv) | 1978-01-21 |
| IE45454B1 (en) | 1982-08-25 |
| GB1556567A (en) | 1979-11-28 |
| LU77796A1 (enrdf_load_stackoverflow) | 1977-10-25 |
| CA1077846A (en) | 1980-05-20 |
| IE45454L (en) | 1978-01-20 |
| IL52550A0 (en) | 1977-10-31 |
| AU2715177A (en) | 1979-01-25 |
| IL52550A (en) | 1981-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3687288T2 (de) | Chinuclidinderivate. | |
| DE3688296T2 (de) | Arzneimittel zur behandlung von erbrechen. | |
| DE602004009426T2 (de) | Kalziumkanalblocker mit zwei benzhydril-teilen | |
| DE3780972T2 (de) | Verwendung von spezifischen n-methyl-d-aspartat-rezeptor-antagonisten zur praevention und behandlung von neurodegeneration. | |
| DE69202441T2 (de) | Melatoninderivate und Kombinationen mit Antiestrogenen zur Behandlung von Brustkarzinoma. | |
| DE3346237A1 (de) | Verwendung von buspiron oder eines pharmazeutisch vertraeglichen saeureadditionssalzes davon zur behandlung extrapyramidaler motorischer stoerungen | |
| DE69428665T2 (de) | Hemmung von CNS-Problemen bei Frauen nach der Menopause | |
| DE69825605T2 (de) | Behandlung der schizophrenie und der psychose | |
| DE69918972T2 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
| DE1793646C3 (de) | Glyoxyldithiosemicarbazone Ausscheidung aus 1518228 | |
| EP0231367B1 (de) | Verwendung von oxirancarbonsäuren zur behandlung der hyperlipämie | |
| DE69226447T2 (de) | NMDA Antagonisten | |
| DE69003924T2 (de) | Verhinderung von Entzugserscheinungen. | |
| DE1767335A1 (de) | Anaesthetikum fuer Tiere | |
| EP0161501A1 (de) | Antiulcermittel zur Behandlung von Geschwüren | |
| DE2732614A1 (de) | Arzneimittel mit wirkung auf das zentralnervensystem | |
| EP0545120A2 (de) | Kombination von 5-HT2-Rezeptorantagonisten und 5-HT1A-Rezeptoragonisten mit neuroprotektiver Wirkung | |
| DE69127285T2 (de) | Verwendung von verbindungen zur behandlung von altersbedingtem gedächtnisschwund und anderen kognitiven störungen | |
| DE2731680A1 (de) | Behensaeureester von phenothiazinderivaten, verfahren zu ihrer herstellung und diese enthaltende arzneimittel | |
| DE2328896A1 (de) | Quaternaere phenylcycloalkylammoniumverbindungen und daraus hergestellte arzneipraeparate | |
| DE3639225A1 (de) | Verwendung von 5-(subst. phenyl)-oxazolidinonderiaten als psychopharmaka | |
| DE69925301T2 (de) | Zusammensetzung von riluzol und alpha-tocopherol | |
| EP0293714A1 (de) | Neue Kombinationspräparate mit antidepressiver Wirkung | |
| DE3782651T2 (de) | Anwendung von n-(2-(diaethylamino)aethyl)-2-methoxy-4((1-h-4,5-dihydro-2-imidazolyl)amino)-5-chlorobenzamid als anxiolytisches und antipsychotisches mittel. | |
| DE2264938A1 (de) | 3-arylaminocarbonyl-4-hydroxy-benzo eckige klammer auf b eckige klammer zu thiacyclohex(3)en-1,1-dioxide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8141 | Disposal/no request for examination |